secwatch.observer — SEC 8-K summary
======================================

Issuer:     REGENERON PHARMACEUTICALS, INC. (REGN)
CIK:        0000872589
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001104659-25-096921
Event type: other_material
Sentiment:  negative
Materiality: 0.45
Item codes: 2.02
LLM model:  deepseek-v4-flash:cloud@v2

Regeneron expects Q3 2025 pre-tax IPR&D charge of ~$83M, reducing EPS by $0.68
------------------------------------------------------------------------------

- Pre-tax acquired IPR&D charge of ~$83M for Q3 2025, primarily from $80M upfront to Hansoh Pharma.
- Charge expected to reduce GAAP and non-GAAP diluted EPS by approximately $0.68 per share.
- Preliminary results subject to financial statement closing procedures and may change.
- Regeneron does not forecast such IPR&D charges due to uncertainty in timing and magnitude.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/0001104659-25-096921-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/872589/000110465925096921/tm2528010d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096921

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer